Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches (Q48389586)

11 February 2018

title

Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches (English)

1 reference

11 February 2018

1 reference

irritable bowel syndrome

1 reference

Alexander C Ford

2

0 references

Michael Camilleri

series ordinal

1

object named as

Michael Camilleri

1 reference

11 February 2018

publication date

20 December 2016

1 reference

11 February 2018

Handbook of experimental pharmacology

published in

1 reference

11 February 2018

volume

239

1 reference

11 February 2018

page(s)

75-113

1 reference

11 February 2018

Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome

cites work

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Spasmolytic and tonic effect of Iberogast (STW 5) in intestinal smooth muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

High Prevalence of Idiopathic Bile Acid Diarrhea Among Patients With Diarrhea-Predominant Irritable Bowel Syndrome Based on Rome III Criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

The proximal colonic motor response to rectal mechanical and chemical stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

The expanded biology of serotonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Effective Constipation Treatment Changes More Than Bowel Frequency: A Systematic Review and Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Different segmental transit times in patients with irritable bowel syndrome and "normal" colonic transit time: is there a correlation with symptoms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Pharmacology of the New Treatments for Lower Gastrointestinal Motility Disorders and Irritable Bowel Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Neuropeptide S receptor induces neuropeptide expression and associates with intermediate phenotypes of functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Genetic susceptibility to inflammation and colonic transit in lower functional gastrointestinal disorders: preliminary analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Irritable bowel syndrome-diarrhea: characterization of genotype by exome sequencing, and phenotypes of bile acid synthesis and colonic transit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Validating biomarkers of treatable mechanisms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

The Prevalence of Celiac Disease Among Patients With Nonconstipated Irritable Bowel Syndrome Is Similar to Controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Biofeedback benefits only patients with outlet dysfunction, not patients with isolated slow transit constipation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Diet rapidly and reproducibly alters the human gut microbiome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Effect of meal ingestion on ileocolonic and colonic transit in health and irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Gut microbiota depletion from early adolescence in mice: Implications for brain and behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Lactose malabsorption in a population with irritable bowel syndrome: prevalence and symptoms. A case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Familial diarrhea syndrome caused by an activating GUCY2C mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Bran and irritable bowel syndrome: time for reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

The serotonin signaling system: from basic understanding to drug development for functional GI disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

A diet low in FODMAPs reduces symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Postinfectious irritable bowel syndrome--a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Altered brain responses in subjects with irritable bowel syndrome during cued and uncued pain expectation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Increased attentional network functioning related to symptom severity measures in females with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Bile acid is a host factor that regulates the composition of the cecal microbiota in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

New insights into bile acid malabsorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Propionate-induced epithelial K+ and Cl−/HCO 3 − secretion and free fatty acid receptor 2 (FFA2, GPR43) expression in the guinea pig distal colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Brain responses to visceral stimuli reflect visceral sensitivity thresholds in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Beneficial effects of soy milk and fiber on high cholesterol diet-induced alteration of gut microbiota and inflammatory gene expression in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Two Randomized Trials of Linaclotide for Chronic Constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

The economic consequences of irritable bowel syndrome: a US employer perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Combat-training increases intestinal permeability, immune activation and gastrointestinal symptoms in soldiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Does meal ingestion enhance sensitivity of visceroperception assessment in irritable bowel syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Clinical practice. Irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

A systematic review of antidepressants in neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Neural and non-neural mediation of propionate-induced contractile responses in the rat distal colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

The Effect of Dietary Intervention on Irritable Bowel Syndrome: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Stress and the Microbiota-Gut-Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Absence of dysfunctional ileal sodium-bile acid cotransporter gene mutations in patients with adult-onset idiopathic bile acid malabsorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Analysis of ileal sodium/bile acid cotransporter and related nuclear receptor genes in a family with multiple cases of idiopathic bile acid malabsorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Chromogranin A promotes peptide hormone sorting to mobile granules in constitutively and regulated secreting cells: role of conserved N- and C-terminal peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Randomized clinical study: Partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Altered Levels of Fecal Chromogranins and Secretogranins in IBS: Relevance for Pathophysiology and Symptoms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

A High-Fat Diet Is Associated With Endotoxemia That Originates From the Gut

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Involvement of serotonin and calcium channels in the intestinal fluid secretion evoked by bile salt and cholera toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Gut endocrine cell population in coeliac disease estimated by immunocytochemistry using a monoclonal antibody to chromogranin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Antibiotic treatment of constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Relationships between pelvic floor symptoms and function in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Chenodeoxycholate in Females With Irritable Bowel Syndrome-Constipation: A Pharmacodynamic and Pharmacogenetic Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Prescribed exercise in people with fibromyalgia: parallel group randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Antidepressants for neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

A randomized, double-blind, placebo-controlled trial of St John's wort for treating irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Post-infectious functional gastrointestinal disorders in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Placebo analgesia in patients with functional and organic abdominal pain: a fMRI study in IBS, UC and healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

The antimicrobial peptides derived from chromogranin/secretogranin family, new actors of innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Nutrient-dependent enhancement of rectal sensitivity in irritable bowel syndrome (IBS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Diagnosis of IBS: symptoms, symptom-based criteria, biomarkers or 'psychomarkers'?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Postinfectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Guidelines on the irritable bowel syndrome: mechanisms and practical management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Laxative properties of indigestible plastic particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Colonic transit time and IBS symptoms: what's the link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

A rat model of chronic postinflammatory visceral pain induced by deoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Abnormal accumulation of intestinal fluid following ingestion of an unabsorbable carbohydrate in patients with irritable bowel syndrome: an MRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

A Klothoβ Variant Mediates Protein Stability and Associates With Colon Transit in Irritable Bowel Syndrome With Diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Pinaverium Reduces Symptoms of Irritable Bowel Syndrome in a Multicenter, Randomized, Controlled Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

New insights into visceral hypersensitivity—clinical implications in IBS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

Association of TNFSF15 polymorphism with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F164_2016_102

21 January 2018

Identifiers

DOI

10.1007/164_2016_102

1 reference

11 February 2018

1 reference

11 February 2018